Description: Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is headquartered in Osborne Park, Australia.
Home Page: www.arovella.com
ALA Technical Analysis
AIM Growth Series
,
Phone:
61 8 6142 5555
Officers
| Name | Title |
|---|---|
| Dr. Michael Baker | CEO, MD & Director |
| Mr. Phillip Hains B Bus, C.A., CA, M.B.A., MBA | Company Sec. & CFO |
| Mr. Stephen John Carter | Consultant |
| Dr. Richard Franklin | Project Director & Member of Scientific Advisory Board |
| Tony Macintyre | GM & CTO |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.3842 |
| Price-to-Sales TTM: | 56.1149 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |